Phenex Pharmaceuticals (FarnesoidX receptor program) Overview

  • Status

  • Acquired/​Merged

  • Latest Deal Type

  • M&A

  • Financing Rounds

  • 1

Phenex Pharmaceuticals (FarnesoidX receptor program) General Information

Description

Provider of treatment for liver disease. The Unit makes small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Acquirer
Gilead Sciences
Primary Office
  • Germany

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Phenex Pharmaceuticals (FarnesoidX receptor program) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Phenex Pharmaceuticals (FarnesoidX receptor program)‘s full profile, request access.

Request a free trial

Phenex Pharmaceuticals (FarnesoidX receptor program) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Phenex Pharmaceuticals (FarnesoidX receptor program)‘s full profile, request access.

Request a free trial